Summary A retrospective case note study of the aetiology and course of children in convulsive status epilepticus (CSE) admitted to a large paediatric intensive care unit (PICU) was undertaken between January 1999 and April 2004. Status epilepticus was defined as a prolonged (>30 min) tonic-clonic seizure irrespective of whether the seizure had stopped prior to admission to PICU. During this period, 137 (74 male) children aged 1 month to 15 years were admitted to PICU with 147 episodes of status epilepticus. Forty-seven of the 137 children (34%) were admitted following a prolonged febrile seizure. Thirty-eight of the 137 children (28%) had a remote symptomatic cause for the CSE, 24 (18%) were admitted for an acute symptomatic cause and 15 (11%) were admitted with an acute exacerbation of a pre-existing idiopathic/ cryptogenic epilepsy. Six children had a progressive encephalopathy and no cause was identified in the remaining 7 of the 137 children (5%). Forty-nine (36%) of the 137 children had pre-existing epilepsy. The mean duration of CSE was 44 min. Forty-nine (36%) children admitted to PICU who had received a benzodiazepine with either phenobarbital or phenytoin, required further treatment to terminate the presenting episode of CSE. Forty-two of these 49 were treated with thiopentone anaesthesia and the remaining 7 with a continuous infusion of midazolam, successfully terminating status in all. No child died. Of the 70 children considered to be previously neurologically and developmentally normal prior to admission, only 1 child demonstrated a new gross neurological abnormality at the time of latest follow-up. Seven patients (5%) developed new or de novo epilepsy.
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Convulsive (tonic-clonic) status epilepticus (CSE) is currently defined as a generalised convulsion lasting 30 min or longer, or repeated tonic-clonic convulsions recurring over 30 min without recovery of consciousness between each convulsion. [1] [2] [3] [4] It is the most common neurological emergency in childhood 5 and is life-threatening with risk of neurological sequelae. 2, 4, 6 There is no precise figure of the incidence of CSE in children, which in part, relates to the definition of status and the population studied. Epidemiological studies have suggested that four to eight children per 1000 may be expected to experience an episode of CSE before the age of 15 years, 7 and in children with first seizures, 12% present with CSE as their first unprovoked seizure. 8 A recent systematic review of the epidemiology of status epilepticus suggested an incidence of 18-20/10,0000 children per year. 9 Approximately 10-25% of children with epilepsy will have at least 1 episode of CSE. 10 Mortality and morbidity due to CSE have declined during the last two decades. Studies in the 1970s suggested a mortality rate of 3-11%, 11, 12 compared with zero in the last few years. 13, 14 More recently, Chin et al. reported a mortality of 3% in 91 children admitted with confirmed status epilepticus; all deaths were in children with an acute symptomatic or progressive cause of CSE. 15 The overall reduced mortality may be explained by a change in the definition of CSE (1 h duration in the 1970s, in contrast to 30 min more recently) and more aggressive treatment of seizures occurring outside hospital and stricter hospital management of CSE with clear and time-defined protocols. Neurological sequelae of CSE (epilepsy, motor deficits, learning difficulties and behaviour problems) tend to be agedependent, occurring in 6% of those over 3 years but in 29% of those under 1 year of age.
11 Important factors that influence neurological outcome are reported to include aetiology, duration of CSE and age. 6 Children under 1 year of age more commonly have an acute symptomatic aetiology, which may explain the relatively poor outcome in this age group. Although the outcome of CSE is primarily determined by its cause, the duration of CSE may also be critical, with longer durations being associated with a higher risk of morbidity and mortality. 16, 17 Delayed treatment of an initial seizure may also increase the frequency of CSE. 6, 18 Early seizure termination is therefore important and this is reflected in the recently published protocols for treating CSE in children. [19] [20] [21] [22] The current approach is therefore to treat every child who is in a tonic-clonic convulsion for more than 5 min as if they were in 'established CSE', to try and prevent the development of persistent status. Early treatment may consequently contribute to a lower mortality and morbidity.
Children in CSE who are admitted to an intensive care unit (ICU) are likely to reflect the severe end of the spectrum; this may reflect the underlying cause or the treatment of the CSE, or both. Consequently, data from admissions to paediatric intensive care units (PICUs) for status epilepticus may clarify some of these issues and may facilitate the development of strategies to try and reduce the duration of CSE and its complications. There are few data on children with CSE admitted to PICU; two reports published over the last 11 years have reported mortality rates of 6% in 147 23 and zero in 186 children; 13 however, a recent study found the case fatality of CSE to be 3% (2-7%). 15 The purpose of this retrospective and observational study was to explore the possible roles of aetiology, course and short-term neurological outcome of children with CSE admitted to an ICU. It was not within the remit of this review to assess the longer-term developmental, cognitive and behavioural outcome of this population.
Patients and methods
The Royal Liverpool Children's Hospital (Alder Hey) (RLCH) is one of the largest children's hospitals in the UK, serving both a large local population of Liverpool (300,000) and a tertiary population with a total population of approximately four million. The hospital has a 20-bed paediatric intensive care unit. The diagnosis and demographic characteristics of all patients admitted to Alder Hey PICU are entered into a computerised database that includes information on diagnosis, duration of admission, duration of ventilatory support, condition at discharge, survival and morbidity. The admission database and discharge summaries during the period 1st January 1999 to 1st April 2004 were searched to identify all children admitted with diagnoses of 'seizure', 'epilepsy', 'convulsions', 'febrile convulsions', 'status epilepticus', 'encephalopathy' and 'coma'. The final criterion for defining the population-base of this study was all children under the age of 16 years admitted to PICU at RLCH, between 1st January 1999 and 1st April 2004 with CSE lasting at least 30 min. All available data, including medical records and intensive care unit charts were reviewed by hand; this included all paramedic (ambulance) and accident and emergency (A + E) records. The review included age, sex, any pre-existing medical diagnosis, the most reliable estimate of the actual duration of CSE, including the time before entering the hospital, and also the aetiology of status, the treatment received both before and on admission to hospital, duration of admission on PICU, and neurological sequelae at the time of discharge and at the time of latest followup. All children with reliable data on CSE were included in the study. Convulsive status epilepticus (CSE) was defined as a prolonged generalised tonicclonic seizure or a series of tonic-clonic seizures without recovery of consciousness between seizures lasting at least 30 min irrespective of whether the seizure had stopped prior to admission to PICU. The duration of CSE included both the time prior to admission through the A + E department and the time in hospital to terminate the status. Termination of status was defined on the basis that all clinical signs of tonic, clonic or tonic-clonic motor activity had stopped.
Electroencephalographic data were also used (to define termination of CSE) in those children with persisting status after admission to PICU. Children under 1 month of age were excluded because of the different aetiologies and outcomes of neonatal seizures. 24 Children with non-convulsive status were also excluded because of the difficulty in determining the precise duration of the seizure activity, its variable presentations and different outcomes.
Treatment of a tonic-clonic seizure, including CSE in RLCH is as used nationally in Great Britain. 22 This protocol was introduced locally and regionally in early 2000, approximately 14 months after the start of this review. Thiopentone and midazolam are the two most commonly used drugs on PICU to treat refractory CSE. Refractory CSE was defined as CSE that had not responded to two doses of benzodiazepine and phenytoin or phenobarbitone. The dose of thiopentone is 4 mg/kg followed by an initial infusion rate of 3 mg/kg/hour. Midazolam is given in an initial dose of 0.3 mg/kg followed by an initial infusion rate of 2-3 mg/kg/min.
Portable 12 or 16-channel EEGs were undertaken in all children considered to have persisting CSE when admitted to PICU and were undertaken between 08.00 and 20.00 h, as there is no overnight EEG service. Continuous cerebral function analysis monitoring (CFAM) was unavailable. Blood levels of antiepileptic drugs (AED) were measured in all children with a pre-existing diagnosis of epilepsy and who were receiving an AED at the time of their admission to PICU.
The paediatric neurology department at Alder Hey children's hospital followed up all patients in CSE admitted to PICU during the study period. Follow up evaluation comprised of a formal neurological examination and a non-standardised assessment of their development or cognitive function. No formal developmental, cognitive or behavioural assessments (including school reports) were used in the follow-up evaluation. Neuroimaging and biochemical data are not reported in this study. All children were followed up for a median duration of 1.5 and a mean of 1.2 years (range, 3 months to 3 years).
Convulsive status epilepticus was classified using a modification of an earlier classification 25 into five aetiological categories: prolonged febrile convulsion (PFC), acute symptomatic (AS), remote symptomatic (RS), idiopathic epilepsy-related (IE-R), progressive encephalopathy (PE) and unclassified (U). These were defined as follows:
Prolonged febrile convulsion (PFC)
CSE during a febrile (temperature above 38 8C) illness in a previously neurologically normal child aged between 6 months and 5 years, and in the absence of defined central nervous system (CNS) infection.
Acute symptomatic (AS)
CSE in a previous neurologically normal child, within a week of an identified acute neurological insult including head trauma, CNS infection, encephalopathy, cerebrovascular disease and metabolic or toxic derangements.
Remote symptomatic (RS)
CSE in a child with previous neurological abnormality. This category included children with cerebral palsy with a febrile illness not of CNS origin and children with obstructed ventriculo-peritoneal shunts for post-haemorrhagic hydrocephalus.
Idiopathic, epilepsy-related (IE-R)
CSE in a child with a prior diagnosis of idiopathic or cryptogenic epilepsy or when the episode of CSE is the second unprovoked seizure that has led to a diagnosis of epilepsy.
Progressive encephalopathy (PE)
CSE in a child with progressive neurodegenerative disease (e.g., late infantile neuronal ceroid lipofuscinosis, subacute sclerosing panencephalitis [SSPE], mitochondrial disease).
Unclassified (C)
CSE that could not be classified into any preceding category.
Statistics
All results are presented in descriptive form.
Results
In the 5 years, 137 children aged 1 month to 15 years were admitted to the PICU with 147 episodes of CSE. Twenty-eight children (20%) were admitted in the period prior to the introduction of the local/regional status epilepticus protocol. Twenty-three of the 137 children (17%) were transfers from other hospitals. The presenting episode of CSE had stopped in only 19 children on presentation to the A + E department. These 19 children were admitted to PICU either because they had required respiratory support in A + E, or because of the severity of their overall clinical condition. Sixty-nine patients required treatment in A + E, which successfully terminated the presenting episode of status. Fifty-seven of these 69 children (82%) were subsequently admitted to PICU for stabilisation and treatment of any underlying illness (e.g., meningitis and encephalitis) or low Glasgow Coma Scale scores and the remaining 12 children (18%) were admitted because of a recurrent tonic-clonic seizure following cessation of the initial CSE in A + E. The remaining 49 patients required additional treatment on PICU for persisting CSE that had not responded to treatment in A + E. All children admitted to PICU following CSE received ventilatory support.
Aetiology of CSE (Fig. 1)
The most common cause was prolonged febrile convulsion (PFC; 47 of the 137 children, 34%). Thirtyeight of the 137 children (28%) were admitted following a remote symptomatic (RS) cause. Twentyfour children (18%) were admitted following an acute symptomatic episode (including meningitis, encephalitis, trauma and anoxia). No patient was found to have hypoglycaemia at the time of presentation to A + E or on PICU. Fifteen children (11%) had an IE-R cause, six children (4%) had a PE and in the remaining 7 of the 137 children (5%), no cause was identified (U category). In the 38 children with a remote symptomatic cause of the CSE, 34 had cerebral palsy and 34 had epilepsy.
Age and sex (Fig. 2) The mean age of the study population was 4 years (median, 2.5 years, S.D., 3 years 7 months; range, 1 month to 15 years). Twenty-eight (20%) patients were under the age of 1 year and 76 (55%) were aged 1-5 years. This group represented the largest subgroup and the majority were classified as PFC and AS. In children aged 5 years and above, RS and I-ER were the most common aetiologies. Seventy-four (54%) of the patients were male.
History of epilepsy
Forty-nine (36%) of the 137 children had a preexisting diagnosis of epilepsy. In 34 (69%) this was symptomatic (28 in the RS and all 6 in the PE group), in nine idiopathic and in the remaining six, cryptogenic. All 49 were receiving antiepileptic drugs (monotherapy in 29, 2 drugs in 12 and 3 drugs in 8 patients). The most commonly used drugs included, in decreasing order of frequency sodium valproate, phenobarbitone, lamotrigine, clonazepam, vigabatrin and carbamazepine. In the 49 patients with preexisting epilepsy, the considered causes for the exacerbation of the epilepsy resulting in the CSE included: unknown in 23 (47%), an intercurrent febrile illness in 18 (37%), a recent change in AED in six (12%) or possible very poor or no concordance with antiepileptic medication (based on non-recordable blood levels of AEDs when measured on presentation in A + E), in two (4%) patients. Data were not collected on whether these children had previously experienced an episode of CSE. In the IE-R category, all 15 children had a prior diagnosis of epilepsy (i.e., in none of these patients did the episode of CSE then lead to a diagnosis of epilepsy). Forty of these 49 children had been given a single dose of rescue medication by their carers prior to presentation in A + E (rectal diazepam in 38 and rectal paraldehyde in two; these latter 2 children had chronic epilepsy and did not usually respond to rectal diazepam).
Duration of CSE
The mean duration of CSE was 44 (median, 40 and range, 30-120) min with the shortest duration in the PFC group (mean, 38 min) and longest in the RS group (mean, 46 min).
Duration of CSE prior to first medical treatment
The mean duration of CSE prior to first medical treatment was 20 (median, 20 and range, 10-30) min. Eighty-two of the 137 patients (59%) had received rescue medication administered either by the child's carers (40 patients) or by the paramedic (ambulance) team prior to presentation in A + E (42 patients).
Duration of admission on PICU
The mean duration of stay on PICU of all patients was 3.5 (median, 2 and range, 1-27) days. The PFC group required the shortest, and the RS group, the longest mean period of admission on PICU (1.5 versus 3.4 days, respectively).
PICU course of CSE
No child died. In 19 of the 147 (13%) episodes of CSE, the child required ventilatory support in A + E because of respiratory insufficiency rather than ongoing seizure activity. The median age of these 19 patients was 1.3 years (range, 1 month to 6.5 years). This did not appear to be related to excessive number or inappropriately high doses of benzodiazepines (based on a review of the parental, paramedic or A + E records; data not shown). Forty-nine children of the 137 children (36%) admitted to PICU required anticonvulsant treatment for ongoing seizure activity and in over 93% of cases this was the initial, presenting episode of status, and not a recurrence of status. Forty-two of these children were treated with thiopentone anaesthesia, successfully terminating the episode of status in all. The mean duration of thiopentone anaesthesia in these cases was 26 h (S.D. 19.4, range 9-72 h). A continuous intravenous infusion of midazolam controlled the status in the remaining 7 children and was administered for a minimum of 24 and a maximum of 72 h.
Recurrent CSE
Following discharge from hospital and during the follow-up period, 10 of the 137 children (7%) experienced 1 further episode of CSE and (six in the RS group, two with AS and two with PE); no child experienced more than 1 further episode of CSE necessitating admission to the PICU during the study period.
Follow-up
The 137 children were followed up for a mean duration of 1.2 years (median, 1.5 and range, 3 months to 3 years). Of the 70 previously neurologically normal children, 64 (91%) demonstrated normal neurological or developmental findings on discharge from PICU to a general ward. Five of the remaining six children demonstrated some impairment of speech, co-ordination or behaviour, which had resolved at the time of the first neurological outpatient review following discharge from hospital. In the one remaining child (in the PFC group), a hemiplegia was evident at discharge and this child was subsequently diagnosed with Rasmussen syndrome. Five children in the RS group (all with a prior background of cerebral palsy), one in the PFC group and one in the AS group (meningitis), developed epilepsy. None of the 49 children treated for refractory CSE developed a new neurological abnormality but two of these 49 children had developed de novo epilepsy at follow-up.
The majority (46 of 47 or 98%) of the children with prolonged febrile CSE demonstrated normal gross neurodevelopmental findings at a median period of 1.3 years following discharge from hospital. However, it must be stressed that none of the children underwent a formal assessment of their developmental or neuropsychological function. The only major motor neurological complication was hemiplegia, which developed in one previously normal 15-month-old infant with a PFC lasting 40 min and in whom no obvious focus of infection was identified; this child was subsequently diagnosed with Rasmussen's syndrome at 3 years of age.
The most common new neurological problem was the onset of new (de novo) epilepsy, occurring in 7 of the 137 (5%) children, which was most prevalent in the RS group (five patients). There was no correlation between the total duration of CSE or duration of CSE prior to first medical treatment and the development of de novo epilepsy.
Intra-hospital transfers
There were no obvious differences in the demographic features or outcome between the 23 children transferred into PICU from other hospitals (data not shown). All categories of CSE were represented in these 23 patients. Three patients required additional treatment on PICU for persisting status. One 15-month-old infant developed a hemiplegia following a PFC (the child with Rasmussen's syndrome).
Children treated before and after the introduction of the local/regional status epilepticus protocol
No formal comparison was undertaken of the 28 children treated before, and the 109 children treated after, the introduction of the protocol in terms of demographic characteristics or outcomes.
Discussion
This retrospective review has demonstrated zero mortality and very low morbidity in over 130 children admitted with CSE to a tertiary centre PICU. Based on the current epidemiological data of children with CSE, and specifically children admitted to an intensive care unit, the confidence intervals (CI) for a population of this size are approximately 1-3%. The two most common causes of CSE were febrile status and a remote symptomatic aetiology. Most children in the RS group had pre-existing epilepsy. These results are very similar to those published recently from Finland.
14 In this study of 186 children, a prolonged tonic-clonic seizure was defined as lasting longer than 5 min, although the mean duration of all seizures (42.6 min) was almost identical to the current study (44 min). No child died in the study from Finland, four children (2.2%) developed permanent neurological sequelae but 40 children (22%) developed de novo epilepsy at a mean follow-up of just over 2 years. In contrast, an earlier 10-year study from the USA undertaken in 147 children (aged three days to 18 years) admitted in status to a PICU found that nine patients (6%) died on PICU, usually due to the underlying cause of the status, rather than the status itself. 23 In addition, 23 of 114 (20%) previously normal children had ''some neurological abnormality'' that was still evident 1 year after the episode of status. Epilepsy was cited as the most common cause of status, occurring in 52 of the 147 patients (35%) followed by ''atypical febrile convulsions'' in 21 (14%). This study did not comment on how many patients developed de novo epilepsy. 23 The reasons for the markedly discrepant rates of de novo epilepsy following the CSE between the Finnish (22%) and the current study (5%) are unclear but may relate to the accuracy of the diagnosis of 'epilepsy' (including the types of epilepsy) and how the diagnosis was established, and the duration of follow-up. In the seven patients with de novo epilepsy in the current study, it was not possible to determine whether the epilepsy in the five children in the RS group was caused by the pre-existing underlying brain dysfunction, or secondary to the episode of CSE.
The reasons for the zero mortality and low morbidity in the current study, despite a mean duration of CSE of 44 min, are likely to be multifactorial, including the children's medical and nursing management on PICU 20, 26 and an early and aggressive approach to the management of CSE and its underlying cause (thereby preventing or reducing any systemic complications). From early 2000, a protocol was introduced for treating a tonic-clonic convulsion (including CSE) in all A + E departments and wards in most hospitals in the Mersey (part of the North West) region (including RLCH) which was identical to that adopted throughout Great Britain later that year. 22 The most important component of this protocol was (and is) the fact that all treatment interventions were (are) prompted by strict, evidencebased time intervals. Unfortunately, no formal comparison was made between the gross neurological outcome of the 28 patients treated before, and the 109 patients treated after the introduction of this protocol in early 2000. It is also possible that the retrospective nature of the current study may not have accurately identified deviations in the status protocol. A recent prospective, population-based study from North London showed that there was considerable deviation from and failure to follow the same national protocol; only one in six children with status epilepticus admitted to their PICU had been appropriately treated (according to the status protocol) prior to arrival in the accident and emergency department. 27 The authors suggested that this may have adversely affected the course and outcome of some of their patients. 27 There was also no obvious difference in the demographic characteristics or gross neurological outcome and incidence of de novo epilepsy between the 23 children transferred in from other hospitals and those managed locally; however, the only child who developed an irreversible neurological complication (hemiplegia) had been transferred in from a nearby hospital but it is likely that she has a progressive condition (Rasmussen's syndrome). It could reasonably have been expected that children transferred in from other hospitals may have been in established CSE for longer or may have been generally sicker (or both) and may also have been exposed to the potential hazards of an intra-hospital transfer. The small number of transferred patients may in part explain the apparent similar outcomes in the two groups.
Both acute and remote symptomatic aetiologies, pre-existing epilepsy and a young age (under 5 years), in CSE are recognised risk factors associated with a poorer neuro-developmental outcome. 5, 21, 28, 29 Although both acute and remote symptomatic causes of the CSE were also identified in the current study, the age at onset, aetiology and duration of CSE were not found to affect gross neurological outcome. The reasons for this may be multiple, including that in the current study, most patients' episode of CSE lasted less than 60 min and the outcome did not include formal developmental or neuropsychological assessments. The authors consider that such assessments would almost certainly have identified significant cognitive or behaviour difficulties in a number of these children.
In 19 of the 147 (13%) episodes of CSE, the child required ventilatory support in A + E because of respiratory insufficiency rather than ongoing seizure activity. The North London study suggested that the risk of respiratory depression appeared to be greater in those children who received more than two doses of benzodiazepines and the authors suggested that clinicians should not disregard pre-hospital treatment of CSE when treating the child on arrival in hospital. 27 However, some caution is required over this suggestion in view of the fact that 83% of their patients had been inappropriately treated prior to arrival--and this could have included inappropriately high, rather than multiple doses, of a benzodiazepine. Data from this current study were not able to confirm or refute the findings of the North London study.
Over one-third of the children admitted to PICU required additional anticonvulsant treatment for continuing CSE. This group could reasonably be regarded as having 'refractory' CSE. The definition of 'refractory' CSE is uncertain but is determined not only by the duration of CSE, but more importantly on the lack of response to the use of first-line anticonvulsants and specifically one (or two) doses of a benzodiazepine plus the use of either phenytoin or phenobarbitone. Forty-nine patients met the criteria for refractory CSE, of whom 42 were treated with thiopentone anaesthesia and the remaining 7 received midazolam. Treatment was successful in all 49 using clinical and EEG criteria. No patient in this study proved refractory to either thiopentone or to midazolam or experienced a recurrence of CSE on PICU. Importantly, none of these 49 patients had developed a new neurological problem and only two had developed de novo epilepsy at latest follow-up; however, none of these children underwent formal developmental or neuropsychological evaluation. Thiopentone is the preferred first line anticonvulsant for refractory CSE in the PICU at RLCH and midazolam is often (but not invariably) used for children with a diagnosis of chronic epilepsy (often in association with cerebral palsy or a progressive encephalopathy), particularly when the child has had previous episodes of CSE that have responded to this drug. Thiopentone and midazolam tend to be the most commonly cited drugs used to treat refractory or persistent CSE, 6, 30, 31 although other drugs, including propofol, may also be effective, particularly in adults. [32] [33] [34] Propofol is not used at RLCH because of concerns about its use in children and the risks of the propofol infusion syndrome and death. 34 There are obvious and a number of limitations to this study. Firstly, it is retrospective and based on case note review, although the PICU database is very accurate and likely to ensure complete ascertainment of all patients admitted to PICU with a diagnosis of 'seizures, convulsions, fits, febrile convulsions, epilepsy, status epilepticus'. All children admitted to the PICU with CSE were discussed with and seen by a paediatric neurologist to confirm the diagnosis of CSE and for subsequent management following discharge from PICU and outpatient follow-up. Secondly, although all the patients underwent neurological examination at follow-up, there was no formal developmental or neuropsychological assessment and school reports were not available. It is therefore possible, if not likely, that this study has not identified those children with attention, short-term memory, planning/processing or other generalised or specific cognitive difficulties, and particularly in the 49 patients with refractory CSE. Finally, neither continuous cerebral function analysis monitoring (CFAM), nor daily portable EEGs were undertaken in this study population, although all patients with refractory CSE underwent at least one portable 12-lead EEG to confirm cessation of electrical seizure activity. However, it could be argued that because the gross neurological outcome of these children was very favourable, it would be reasonable to question the role and importance of CFAM and serial EEG investigations in the management of, and influence on outcome in this population although it is recognised that the lack of formal neuropsychological data may militate against this argument. It could also be reasoned that, if more intensive EEG or CFAM data (in demonstrating continuing electrical seizure activity), had prompted more aggressive treatment (e.g., attempting to obtain electrical burst-suppression with higher doses of thiopentone), this could have resulted in additional, iatrogenic complications with an increased risk of both mortality and morbidity. 35 In summary, this retrospective review of a large number of patients has suggested that the current emergency and intensive care management of CSE in children appears to be associated with a good outcome, similar to recent data, and represents a marked improvement when compared to findings published over 30 years ago. It is particularly encouraging that none of the 49 patients with refractory CSE died or suffered a permanent neurological deficit although it is possibly that 1 or more may have developed developmental, cognitive or behavioural sequelae as a direct result of the status and that have not been identified in this study. It would be important to undertake a prospective study on all children admitted to PICU in not only CSE but also refractory CSE, and to evaluate their cognitive and behavioural outcomes using standardised neuropsychological assessments. It would also be useful to document the incidence and types of de novo epilepsy developing in this population.
